Research library

1,777 reports · By date added

Bank of America: LG Innotek: Currency pressure squeezes Apple business profits; AI substrate growth remains a longer-term prospect

Third-quarter revenue rose 19% year on year, but operating profit fell 53%. Bank of America downgraded the stock from Buy to Neutral and cut its price target from 1.25 million won to 420 thousand won: won appreciation is eroding profits from the Apple business, while a meaningful contribution from AI substrate capacity expansion is not expected until the end of 2028.

Goldman Sachs: High-end copper-clad laminates drive better-than-expected profits; Goldman Sachs backs expansion and price increases at two Taiwanese manufacturers

Elite Material and Taiwan Union Technology reported third-quarter core operating profits 6% and 16% above Goldman Sachs’ expectations, respectively. Goldman expects product upgrades and price increases to lift both companies’ fourth-quarter gross margins to about 41%, though their capacity rollout schedules and customer project transitions differ.

Guotai Haitong Securities: Ampire: Robot force sensors delivered in volume, while earnings recovery still hinges on scaling up new automotive products

Guotai Haitong Securities expects Ampire’s net profit attributable to shareholders to fall 74.1% year on year in 2026, before recovering over the following two years as new pressure sensors scale up and the force sensor business expands. The company has delivered several types of force sensors in volume, while the size of the robot market still depends on complete robot shipments.

Citi: SK hynix profit rises again in the third quarter; Citi raises earnings forecasts

Higher memory prices and a greater share of high-value products drove a 38% quarter-on-quarter increase in SK hynix’s third-quarter operating profit. Citi raised its earnings forecasts for the fourth quarter and the following two years, while the company announced an annual shareholder return plan of approximately 100 trillion won.

Citi: BioNTech’s breast cancer trial meets its primary endpoint, but benefit is limited; Citi sees manageable impact on the stock

The phase III T-pam trial met its primary endpoint, but the progression-free survival benefit was limited and the incidence of interstitial lung disease was relatively high. Citi believes previously lowered expectations have softened the impact of the results on BioNTech, while also watching the endometrial cancer opportunity and other oncology programs.

A-share rebound gains volume: Robotics leads, with further gains dependent on continued funding

The ChiNext Index rose more than 3%, while turnover on the two mainland exchanges increased by 167.5 billion yuan from the previous trading day. The robotics theme drove a broader spread of first-time limit-up stocks, but follow-through in high-priced stocks was weak. The September rebound ended after volume contracted, making sustained turnover the key question this time.